Table 3 Weekly pre-dose morning and evening PEF response (L/min) after 4 weeks of treatment for Study 1222.6
n | Difference from placebo | ||||
|---|---|---|---|---|---|
Mean (SE) | Mean (SE) | 95 % CI | p value | ||
Morning PEF | |||||
Placebo | 54 | 368.18 (5.71) | |||
Olodaterol 2 μg | 61 | 384.42 (5.38) | 16.24 (7.84) | 0.80, 31.68 | 0.0393 |
Olodaterol 5 μg | 60 | 396.06 (5.42) | 27.88 (7.88) | 12.38, 43.38 | 0.0005 |
Olodaterol 10 μg | 59 | 404.26 (5.47) | 36.07 (7.91) | 20.51, 51.63 | <0.0001 |
Olodaterol 20 μg | 61 | 411.13 (5.38) | 42.94 (7.85) | 27.50, 58.39 | <0.0001 |
Evening PEF | |||||
Placebo | 54 | 384.08 (5.59) | |||
Olodaterol 2 μg | 61 | 407.05 (5.26) | 22.97 (7.67) | 7.88, 38.06 | 0.0030 |
Olodaterol 5 μg | 60 | 408.68 (5.30) | 24.60 (7.70) | 9.45, 39.75 | 0.0016 |
Olodaterol 10 μg | 59 | 420.88 (5.34) | 36.81 (7.73) | 21.60, 52.02 | <0.0001 |
Olodaterol 20 μg | 61 | 426.58 (5.26) | 42.51 (7.68) | 27.40, 57.61 | <0.0001 |